EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis

Walter Masson iD, Martín Lobo iD, Gustavo Giunta iD, Leandro Barbagelata iD, Juan P Nogueira iD

Advances in Therapy · 2026

DOI: 10.1007/s12325-025-03418-x ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Advances in Therapy, 2026. Verfasst von Walter Masson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Italiano de Buenos Aires, Perón 4190, C1199ABB, Ciudad Autónoma de Buenos Aires, Argentina. walter.masson@hospital…. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Anticholesteremic Agents, Hypercholesterolemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Pharmacological inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) is a well-established strategy for achieving substantial reductions in low-density lipoprotein cholesterol (LDL-C). Recently, novel oral PCSK9 inhibitors have emerged, providing new evidence regarding their lipid-lowering efficacy and safety. METHODS: This systematic review and meta-analysis was conducted in accordance with PRISMA guidelines. Randomized clinical trials evaluating oral PCSK9 inhibitors and reporting percentage changes in lipid parameters and/or adverse events were included. A qualitative synthesis was performed for all studies meeting predefined eligibility criteria, followed by a quantitative synthesis of studies with sufficient data for statistical pooling. RESULTS: Seven randomized clinical trials were included in the qualitative analysis, of which four were eligible for meta-analysis. Five oral PCSK9 inhibitors were identified. Three agents (MK-0616, AZD0780, and NNC0385-0434) contributed to the quantitative analysis, while two (DC371739 and CVI-LM001) were assessed descriptively. Compared with placebo, oral PCSK9 inhibitors significantly reduced LDL-C [mean difference (MD) - 55.7; 95% confidence interval (CI) - 59.3 to - 52.1; I2 = 14%)] and apolipoprotein B (MD - 46.9; 95% CI - 54.6 to - 39.2; I2 = 72.9%). They also lowered non-high-density lipoprotein cholestero (MD - 49.4; 95% CI - 57.4 to - 41.5; I2 = 50.3%), triglycerides (MD - 13.2; 95% CI - 21.4 to - 5.0; I2 = 0%), and lipoprotein(a) (MD - 24.9; 95% CI - 34.9 to - 15.0; I2 = 77.6%). Across trials, no differences in safety outcomes were observed between oral PCSK9 inhibitors and placebo. CONCLUSION: Oral PCSK9 inhibitors demonstrate lipid-lowering efficacy and safety comparable to that of currently approved injectable PCSK9 therapies. These findings support their potential as a convenient and effective alternative, although current evidence remains limited to early-phase studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsAnticholesteremic AgentsHypercholesterolemiaHumansCholesterol, LDLRandomized Controlled Trials as TopicAdministration, OralProprotein Convertase 9

Stichwörter der Autor:innen

LDL-CMeta-analysisOral PCSK9 inhibitorsSafety

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanCholesterol, LDLAnticholesteremic AgentsProprotein Convertase 9

Autor:innen und Institutionen

  • Department of Cardiology, Hospital Italiano de Buenos Aires, Perón 4190, C1199ABB, Ciudad Autónoma de Buenos Aires, Argentina. walter.masson@hospitalitaliano.org.ar.
  • Dirección General de Educación del Ejército Argentino, Buenos Aires, Argentina.
  • Department of Cardiology, Fundación Favaloro, Buenos Aires, Argentina.
  • Department of Cardiology, Hospital Italiano de Buenos Aires, Perón 4190, C1199ABB, Ciudad Autónoma de Buenos Aires, Argentina.
  • Endocrinology, Nutrition and Metabolism Research Center, Faculty of Health Sciences, Universidad Nacional de Formosa, Formosa, Argentina.
  • International University of the Americas, San José, Costa Rica.

ORCID-Profile: Walter Masson, Martín Lobo, Gustavo Giunta, Leandro Barbagelata, Juan P Nogueira

Zitieren

APA

Masson, W., Lobo, M., Giunta, G., Barbagelata, L., & Nogueira, J. P. (2026). Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. Advances in Therapy. https://doi.org/10.1007/s12325-025-03418-x

Vancouver

Masson W, Lobo M, Giunta G, Barbagelata L, Nogueira JP. Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. Advances in Therapy. 2026. doi:10.1007/s12325-025-03418-x

BibTeX
@article{Masson2026,
  author = {Masson, Walter and Lobo, Martín and Giunta, Gustavo and Barbagelata, Leandro and Nogueira, Juan P},
  title = {Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis},
  journal = {Advances in Therapy},
  year = {2026},
  doi = {10.1007/s12325-025-03418-x}
}
Kostenlos starten →